Current Report Filing (8-k)
April 06 2023 - 6:01AM
Edgar (US Regulatory)
0001855644
false
00-0000000
0001855644
2023-04-05
2023-04-05
0001855644
us-gaap:CommonClassAMember
2023-04-05
2023-04-05
0001855644
us-gaap:WarrantMember
2023-04-05
2023-04-05
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
Ordinary Shares [Member]
Warrants [Member]
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT
OF 1934
Date of Report (Date of earliest
event reported): April 5, 2023
Zura
Bio Limited
(Exact name of registrant
as specified in its charter)
| Cayman Islands |
|
001-40598 |
|
N/A |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S. Employer
Identification No.) |
4225 Executive Square, Suite
600
La Jolla, CA 92037
(Address of principal executive
offices, including zip code)
(858) 247-0520
(Registrant’s telephone
number, including area code)
(Former name or former address,
if changed since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written
communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name
of each exchange on which registered |
| Class A Ordinary Shares, par value $0.0001 per share |
|
ZURA |
|
The Nasdaq Stock Market |
| Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share |
|
ZURAW |
|
The Nasdaq Stock Market |
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
Item 9.01
Financial Statements and Exhibits.
(a) Financial Statements of Business Acquired.
As previously disclosed in the Current Report
on Form 8-K filed by the registrant on March 24, 2023, Zura Bio Limited, a limited company incorporated under the laws of England and
Wales (“Zura”), and JATT Acquisition Corp, a Cayman Islands exempted company (“JATT”), consummated a business
combination on March 20, 2023.
The audited consolidated financial statements
of Zura as of December 31, 2022 and for the period from January 18, 2022 (date of inception) to December 31, 2022 are set forth herein
as Exhibit 99.1 and are incorporated herein by reference.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
Zura Bio Limited |
| |
|
| Dated: April 5, 2023 |
|
|
| |
By: |
/s/ Someit Sidhu |
| |
|
Someit Sidhu |
| |
|
Chief Executive Officer |
Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Dec 2024 to Jan 2025
Zura Bio (NASDAQ:ZURA)
Historical Stock Chart
From Jan 2024 to Jan 2025
